Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT05205343
Recruiting Observational

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

NCT05205343 · tracked via the Priya Life Science South Korea tracker
Sponsor
M.D. Anderson Cancer Center
Phase
Observational
Started
2022-05-11
Last updated
2026-08-21

Condition(s) studied

GastrostomyGastricGastroEsophageal Cancer

Investigational drug(s) / intervention(s)

Standard of CareControl Group

Standard of Care: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery

Control Group: complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery

Study summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion: 1. Able to speak and read English, Spanish, Japanese or Korean 2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention 3. Age ≥ 18 Exclusion: 1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract 2. Participants with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent 3. Participants deemed unable to comply with study and/or follow-up procedures, at investigators' discretion 4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Primary outcome measure(s)

  • (MDASI-GI) MD Anderson Symptom Inventory Questionnaire — 3 months after surgery
    Appetite level (reported on a 0-10 scale, in Q8 of MDASI-GI) scale 0-not present-10 as bad as you can image

Trial sites (4)

FacilityCityRegionStatus
Mayo Clinic in Rochester Rochester Minnesota Active Not Recruiting
M D Anderson Cancer Center Houston Texas Recruiting
Keio University School of Medicine Tokyo Japan Recruiting
Yonsei University College of Medicine Soeul South Korea Recruiting

Other trials for the same condition

EOI Block for Laparoscopic Gastrostomy Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Recruiting
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma Recruiting
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05205343 on ClinicalTrials.gov ↗ ← All trials in South Korea